Disease relevance of Growth hormone releasing peptide

• It is concluded that GHRP stimulated GH release in the majority of acromegaly patients [1].
• Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters [2].
• Growth hormone-releasing hexapeptide (GHRP-6) increases intracellular calcium concentrations in cultured cells from human pituitary adenomas of different types [3].
• Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism [4].
• GH-releasing peptide (GHRP-6)-induced ACTH release in patients with addison's disease: effect of glucocorticoid withdrawal [5].

Psychiatry related information on Growth hormone releasing peptide

• Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa [6].

High impact information on Growth hormone releasing peptide

• Ghrelin is a GH-releasing peptide that also has an important role as an orexigenic hormone-stimulating food intake [7].
• Based upon a simplified biomathematical model of three-peptide control, the current outcomes suggest that women maintain greater GHRH potency, GHRP efficacy, and opposing SS outflow than men [8].
• We previously showed that the latter can be reactivated by brief infusion of GH-releasing peptide (GHRP-2) and TRH [9].
• The synthetic hexapeptide GH-releasing peptide (GHRP) stimulates a dose-dependent release of GH in humans in vivo and in animals both in vitro and in vivo via a specific receptor in the hypothalamus and pituitary [10].
• We studied the effects of varying doses (0-1.0 microgram/kg) of hexarelin, a novel GH-releasing peptide, administered iv to healthy adult males on GH, PRL, and cortisol release [11].

Biological context of Growth hormone releasing peptide

• Ghrelin is a novel GH-releasing peptide that may also induce vasodilation and a positive energy balance through GH-independent mechanisms [12].
• Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites [13].
• Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat [14].
• Using a specific plasma HPLC/fluorescence assay, the iv and sc pharmacokinetics of SK&F 110679 were investigated in both species [15].
• We cloned a fragment of the rat GH-releasing peptide (GHRP) receptor homologue and examined the tissue distribution of GHRP receptor mRNA in rats [16].

Anatomical context of Growth hormone releasing peptide

• In this study, the effects of a second generation GH-releasing peptide, Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2(GHRP-1), on cAMP, intracellular Ca2+ ([Ca2+]i), and GH release were examined using rat pituitary gland static monolayer cell cultures [17].
• Previously, we demonstrated that the synthetic hexapeptide GH-releasing peptide (GHRP-6) activates a subpopulation of arcuate neurones, as reflected by increased electrical activation and by the detection of Fos protein in cell nuclei [18].
• The differing timing of the neuroendocrine or behavioural response to hexarelin would suggest the existence of different subtypes of central nervous system GH-releasing peptide receptors [19].
• Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes [20].

Associations of Growth hormone releasing peptide with other chemical compounds

• Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone [21].
• Growth hormone release induced by growth hormone-releasing hexapeptide is not mediated by thyrotropin-releasing hormone in neonatal rats [22].
• GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide [23].
• OBJECTIVE: Hexarelin is a recently synthesized small growth hormone releasing peptide (GHRP) (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys- NH2) [24].
• Example absorption studies that are described are mannitol, cephalexin, the growth hormone-releasing peptide SK&F 110679 and two GPIIb/IIIa antagonist peptides SK&F 106760 and SK&F 107260 [25].

Gene context of Growth hormone releasing peptide

• Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action [26].
• This hypothesis was further explored by investigating the effects of continuous i.v. infusion of GHRH, GHRP, TRH and their combinations for several days [27].
• In the rat, the synthetic GH secretagogue GH-releasing peptide (GHRP-6) acts centrally to activate a subpopulation of arcuate neurones as reflected by increased electrical activation and by the detection of Fos protein in cell nuclei [28].
• In the present study, the possible somnogenic effects induced under similar conditions by GH-releasing peptide (GHRP) were investigated in seven young healthy men [29].
• Changes in plasma concentrations of GH and insulin in response to feeding and stimulation with GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-6, a ligand for endogenous GH secretagogue receptors) were compared between 3-week-old (milk-fed) and 12-week-old (concentrate and hay-fed) calves [30].

Analytical, diagnostic and therapeutic context of Growth hormone releasing peptide

• A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism [31].
• Further additional investigations of 'second level' (i.e. GH secretory profile, GH response to a GH-releasing peptide) can be retained to validate or exclude rGH administration or for the early diagnosis of infrequent endogenous GH hypersecretion [32].
• For each treatment schedule, before treatment, during treatment (24 h from the previous rhGH injection) and 1, 5 and 10 days after treatment, all dogs received an intravenous injection of a GHRP, EP51216 (125 microg/kg) [33].
• Growth hormone-releasing peptide 6 (GHRP-6) is a synthetic hexapeptide with a potent GH-releasing activity after intravenous, subcutaneous, intranasal and oral administration in man [34].
• Determination of growth hormone-releasing hexapeptide by reversed-phase high-performance liquid chromatography with electrochemical detection [35].

References